TY - JOUR
T1 - Efficacy of high-sensitivity troponin T in identifying very-low-risk patients with possible acute coronary syndrome
AU - Peacock, W. Frank
AU - Baumann, Brigette M.
AU - Bruton, Deborah
AU - Davis, Thomas E.
AU - Handy, Beverly
AU - Jones, Christopher W.
AU - Hollander, Judd E.
AU - Limkakeng, Alexander T.
AU - Mehrotra, Abhi
AU - Than, Martin
AU - Ziegler, Andre
AU - Dinkel, Carina
N1 - Funding Information:
completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Peacock reports grants from Roche Inc during the conduct of the study; grants and personal fees from Roche Inc and Alere Inc; and personal fees from Abbott Inc, Beckman Inc, and Prevencio Inc outside the submitted work. Dr Baumann reports grants from Roche during the conduct of the study (payment for enrollment of patients in this investigation to cover salary support of research coordinator). Ms Bruton reports previous employment with Roche Diagnostics. Dr Handy reports funding from Roche Diagnostics to support laboratory personnel and supplies for the study (study design and statistical analysis), during the conduct of the study and has participated in other studies with Roche Diagnostics in which funding to support laboratory personnel and supplies (study design and statistical analysis) was provided for the study outside the submitted work. Dr Jones reports grants from Roche Diagnostics Inc during the conduct of the study and grants from Janssen and AstraZeneca outside the submitted work. Dr Hollander reports grants from Roche during the conduct of the study and grants from Alere, Siemens, Roche, and Trinity outside the submitted work. Dr Limkakeng reports grants from Roche Diagnostics International Ltd during the conduct of the study; consultancy from ZS Pharma and Biomerieux; and grants/grants pending from Roche Diagnostics, Abbott Laboratories, Bristol Meyers Squibb, Siemens Healthcare, Department of Defense/Henry Jackson Foundation, and Janssen Pharmaceuticals outside the submitted work. Dr Mehrotra reports sponsored research from Roche during the conduct of the study. Dr Than reports grants and personal fees from Abbott and Roche (funding for clinical trials, payment for speaking, and funding for education), grants from Beckman (funding for clinical trials, funding for education), and personal fees from Alere (payment for speaking and funding for education) outside the submitted work. Dr Ziegler reports employment with Roche Diagnostics during the conduct of the study. Ms Dinkel reports employment by Roche Diagnostics. No other disclosures were reported.
Publisher Copyright:
© 2017 American Medical Association. All rights reserved.
PY - 2018/2
Y1 - 2018/2
N2 - IMPORTANCE Physicians need information on how to use the first available high-sensitivity troponin (hsTnT) assay in the United States to identify patients at very low risk for 30-day adverse cardiac events (ACE). OBJECTIVE To determine whether a negative hsTnT assay at 0 and 3 hours following emergency department presentation could identify patients at less than 1% risk of a 30-day ACE. DESIGN, SETTING, AND PARTICIPANTS A prospective, observational study at 15 emergency departments in the United States between 2011 and 2015 that included individuals 21 years and older, presenting to the emergency department with suspected acute coronary syndrome. Of 1690 eligible individuals, 15 (no cardiac troponin T measurement) and 320 (missing a 0-hour or 3-hour sample) were excluded from the analyses. EXPOSURES Serial hsTnT measurements (fifth-generation Roche Elecsys hsTnT assay). MAIN OUTCOMES AND MEASURES Serial blood samples from each patientwere collected after emergency department presentation (once identified as a potential patient with acute coronary syndrome) and 3 hours, 6 to 9 hours, and 12 to 24 hours later. Adverse cardiac events were defined asmyocardial infarction, urgent revascularization, or death. The upper reference level for the hsTnT assay, defined as the 99th percentile, was established as 19 ng/L in a separate healthy US cohort. Patients were considered ruled out for acutemyocardial infarction if their hsTnT level at 0 hours and 3 hours was less than the upper reference level. Gold standard diagnoses were determined by a clinical end point committee. Evaluation of assay clinical performance for acutemyocardial infarction rule-out was prespecified; the hypothesis regarding 30-day ACE was formulated after data collection. RESULTS In 1301 healthy volunteers (50.4%women; median age, 48 years), the upper reference level was 19 ng/L. In 1600 patients with suspected acute coronary syndrome (48.4%women; median age, 55 years), a single hsTnTlevel less than 6 ng/L at baseline had a negative predictive value for AMI of 99.4%. In 974 patients (77.1%) with both 0-hour and 3-hour hsTnT levels of 19 ng/L or less, the negative predictive value for 30-day ACE was 99.3%(95%CI, 99.1-99.6). Using sex-specific cutpoints, C statistics for women (0.952) and men (0.962) were similar for acutemyocardial infarction. CONCLUSIONS AND RELEVANCE A single hsTnT level less than 6 ng/L was associated with a markedly decreased risk of AMI, while serial levels at 19 ng/L or less identified patients at less than 1% risk of 30-day ACE.
AB - IMPORTANCE Physicians need information on how to use the first available high-sensitivity troponin (hsTnT) assay in the United States to identify patients at very low risk for 30-day adverse cardiac events (ACE). OBJECTIVE To determine whether a negative hsTnT assay at 0 and 3 hours following emergency department presentation could identify patients at less than 1% risk of a 30-day ACE. DESIGN, SETTING, AND PARTICIPANTS A prospective, observational study at 15 emergency departments in the United States between 2011 and 2015 that included individuals 21 years and older, presenting to the emergency department with suspected acute coronary syndrome. Of 1690 eligible individuals, 15 (no cardiac troponin T measurement) and 320 (missing a 0-hour or 3-hour sample) were excluded from the analyses. EXPOSURES Serial hsTnT measurements (fifth-generation Roche Elecsys hsTnT assay). MAIN OUTCOMES AND MEASURES Serial blood samples from each patientwere collected after emergency department presentation (once identified as a potential patient with acute coronary syndrome) and 3 hours, 6 to 9 hours, and 12 to 24 hours later. Adverse cardiac events were defined asmyocardial infarction, urgent revascularization, or death. The upper reference level for the hsTnT assay, defined as the 99th percentile, was established as 19 ng/L in a separate healthy US cohort. Patients were considered ruled out for acutemyocardial infarction if their hsTnT level at 0 hours and 3 hours was less than the upper reference level. Gold standard diagnoses were determined by a clinical end point committee. Evaluation of assay clinical performance for acutemyocardial infarction rule-out was prespecified; the hypothesis regarding 30-day ACE was formulated after data collection. RESULTS In 1301 healthy volunteers (50.4%women; median age, 48 years), the upper reference level was 19 ng/L. In 1600 patients with suspected acute coronary syndrome (48.4%women; median age, 55 years), a single hsTnTlevel less than 6 ng/L at baseline had a negative predictive value for AMI of 99.4%. In 974 patients (77.1%) with both 0-hour and 3-hour hsTnT levels of 19 ng/L or less, the negative predictive value for 30-day ACE was 99.3%(95%CI, 99.1-99.6). Using sex-specific cutpoints, C statistics for women (0.952) and men (0.962) were similar for acutemyocardial infarction. CONCLUSIONS AND RELEVANCE A single hsTnT level less than 6 ng/L was associated with a markedly decreased risk of AMI, while serial levels at 19 ng/L or less identified patients at less than 1% risk of 30-day ACE.
UR - http://www.scopus.com/inward/record.url?scp=85043500459&partnerID=8YFLogxK
U2 - 10.1001/jamacardio.2017.4625
DO - 10.1001/jamacardio.2017.4625
M3 - Article
C2 - 29238804
AN - SCOPUS:85043500459
SN - 2380-6583
VL - 3
SP - 104
EP - 112
JO - JAMA Cardiology
JF - JAMA Cardiology
IS - 2
ER -